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ABSTRACT A new series of 5-aryl and 5-arylethenylisoxazole carboxylate derivatives was synthesized
and evaluated for in vitro activity against Mycobacterium tuberculosis H37Rv. Several compounds exhibited
minimum inhibitory concentrations in the low micromolar range (2.3–11.4 mM). A variety of substituents
introduced around the isoxazole ring allowed the delineation of preliminary SARs for this new series of
compounds. Drug Dev Res 74 : 162–172, 2013. © 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Tuberculosis (TB) is a chronic and often deadly
infectious disease caused by various species ofMycobac-
terium, mainly Mycobacterium tuberculosis (Mtb)
[Russell et al., 2010]. The World Health Organization
(WHO) has estimated that one-third of the world’s
population is infected with Mtb, resulting in 9.4 million
new TB cases and 1.7 million deaths from TB in 2009, for
the most part in developing countries [World Health
Organization, 2010; World Health Organization, 2010/
2011].
Despite the severe worldwide impact of TB, it
remains a neglected disease as demonstrated by the
evidence that no new anti-TB drugs have been intro-
duced in therapy over the past 40 years [Janin, 2007;
Spigelman, 2007] with rifampin (RMP), discovered in
1966, the most recent drug in this field [Maggi et al.,
1966]. At present, only a few drug candidates are in
Phase II clinical trials, e.g., PA-824 [Stover et al., 2000]
and TMC-207 [Andries et al., 2005] (Fig. 1).
For many years, TB was considered a poverty-
related disease, but it now occurs in the developed
world. This is due to several reasons, the most impor-
tant being the development of new virulent strains,
resistant to antitubercular drugs, as well as the stream
of immigrants from countries where TB is endemic.
In addition, the recurrence of TB is directly connected
to the explosive spread of HIV as the number of HIV-
positive patients coinfected with Mtb is constantly rising
[Brooks et al., 2009]. WHO reports that one third of
HIV-infected people are coinfected with TB [World
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Health Organization, 2002], and 90% of these die
within a few months of the appearance of clinical symp-
toms. This situation has prompted the WHO to declare
TB as a global emergency [Janin, 2007].
The current standard therapy, Directly Observed
Therapy Short-course [World Health Organization,
2009] is based on a combination of isoniazide (INH),
Rifampin (RMP), pyrazinamide, and ethambutol (or
streptomycin) for 2 months followed by further treat-
ment with INH and RMP for an additional 4–7
months. This long treatment regimen is necessary
because of the presence of a nonreplicating persistent
Mtb phenotype (NRP-TB) [Wayne and Sohaskey,
2001] is often associated with poor patient compliances
that contribute to the development of multidrug
resistance. There are two types of drug resistance:
multidrug resistant TB (MDR-TB) and extensively
drug resistant TB (XDR-TB) [Johnson et al., 2006;
Dorman and Chaisson, 2007]; the former defined as
resistance to at least INI and RMP (MDR-TB) and
the latter including concomitant resistance to any
fluoroquinolone and at least one second-line drug, e.g.
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Fig. 1. Examples of anti-TB agents.
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kanamycin, amikacin, or capreomycin (XDR-TB).
These data highlight the need for new, safer, and more
potent anti-TB agents with novel mechanisms of
action.
Many classes of organic compounds have been
synthesized and tested as anti-TB agents, and in par-
ticular nitrogen heterocycles derivatives such as isox-
azolines or isoxazoles have been described as good in
vitro antitubercular agents [Johar et al., 2005; Janin,
2007; Eswarana et al., 2010]. Some representative com-
pounds with this scaffold are shown in Figure 1. The
isoxazolines A and B [Tangalapally et al., 2007] and the
isoxazole derivatives C [Pieroni et al., 2009] and D [Lil-
ienkampf et al., 2010] had interesting levels of activity
against Mtb with minimum inhibitory concentration
(MIC) values in the low or submicromolar range.
In this article, we describe the synthesis and
the biological activity of a new series of anti-TB
compounds with an isoxazole scaffold (Fig. 1, struc-
ture E), structurally related to compounds C and D.
Various substituents were introduced around the isox-
azole core in order to find the best substitution
pattern and to define the importance of different
substituents.
MATERIALS AND METHODS
Chemistry
All the final compounds were synthesized as
reported in Figures 2 and 3. Figure 2 shows the syn-
thetic procedure leading to the 4-benzoyl-5-
styrylisoxazoles 2a–f and 4a–c. The precursors were
represented by previously described isoxazoles 1a,b
[Renzi et al., 1968; Dal Piaz et al., 1991], which were
condensed with the appropriate arylaldehydes to give
the corresponding vinyl derivatives 2a–f. Hydrolysis of
2a and 2f gives intermediate carboxylic acids 3a,b
which, in turn, were transformed into the ester deriva-
tives 4a–c using the appropriate alcohol and conc.
H2SO4 at 80°C. Figure 2 shows the synthesis of the
4-unsubstituted derivatives 8a–g and 10 a–e. The key
intermediates 7a–g (7a [Fatutta and Balestra, 1958];
7b [Thormann et al., 2008]; 7c [Deavegowda et al.,
2010]; 7f [Janculev and Podolesov, 1961]; 7g [Patil
et al., 2007] were obtained by condensation of commer-
cially available 5a–g and diethyl oxalate 6 [Fatutta and
Balestra, 1958] and transformed into the final isoxazoles
8a–g by treatment with hydroxylamine hydrochloride
in ethanol and H2SO4. Finally, for compounds 8a–e, a
2           Ar                   X
          
a          Ph                    H
b          4-Cl-Ph           H
c          3-Cl-Ph           H
d                                 H
e                                      Cl
f                                  H
3           Ar
a          Ph
b
N
O
EtOOC
CH3
O
X
1a,b
N
O
EtOOC
CH=CH-Ar
O
X
2a-f
A
N
O
HOOC
CH=CH-Ar
O
B
3a,b
for 2a and 2f
N
O
ROOC
CH=CH-Ar
O
4a-c
4       Ar              R
a       Ph            CH3
b       Ph            iC3H7
c                        iC3H7
1      X
a      Ph
b      H
C
Fig. 2. Reagent and conditions: (A) ArCHO, EtONa, EtOH, 0°C, 2–20 h; (B) NaOH, EtOH, r.t., 1 h; (C) ROH, H2SO4, 80°C, 30–90 min.
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further transformation in the corresponding isopropyl
esters (10a–e) was performed following the same pro-
cedure described for compounds 4a–c.
Experimental
All melting points were determined on a Büchi
apparatus and are uncorrected. 1H-NMR spectra were
recorded with an Avance 400 instrument (Bruker
Biospin Version 002 with SGU, Bruker AXS Inc.,
Madison, WI USA). Chemical shifts are reported in
ppm, using the solvent as internal standard. Extracts
were dried over Na2SO4, and the solvents were removed
under reduced pressure. Merck F-254 commercial
plates (Merck-Gruppe, Darmstadt, Germany) were
used for analytical thin layer chromatography (TLC)
to follow the reaction course. Silica gel 60 (Merck
70–230 mesh) was used for column chromatography.
Microanalyses were performed with a Perkin-Elmer 260
elemental analyzer (Perkin-Elmer, Waltham, MA USA)
for C, H, and N. Results were within 0.4% of the
theoretical values unless otherwise stated. Reagents and
starting materials were commercially available.
General Procedures for 2a–f
To a cooled (0°C) and stirred mixture of 1a,b
[Renzi et al., 1968; Dal Piaz et al., 1991] (3.86 mmol)
and the appropriate arylaldehyde (3.86 mmol) in
4–6 ml of anhydrous EtOH, a solution of sodium ethox-
ide, obtained from sodium (7.72 mmol) and anhydrous
EtOH (5 ml), was slowly added. The mixture was
stirred at 0°C for 2–20 h, then it was acidified with 6 N
HCl and diluted with 30 ml of cold water. The final
compounds were recovered by suction and purified by
crystallization.
4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid
Ethyl Ester, 2a
Yield = 67%; mp = 56°C (EtOH); 1H-NMR
(DMSO-d6) d 0.97 (t, 3H, CH3CH2, J = 7.2 Hz), 4.07
(q, 2H, CH3CH2, J = 7.2 Hz), 7.13 (d, 1H, CH = CH,
J = 16.8 Hz), 7.45–7.49 (m, 3H, Ar), 7.58 (m, 2H, Ar),
7.62–7.78 (m, 4H: 3H, Ar; 1H, CH = CH), 7.82 (m,
2H, Ar). MS m/z 348 [M+]. Anal. Calcd for C21H17NO4:
C, 72.61; H, 4.93; N, 4.03. Found C, 7.40; H, 4.92;
N, 4.04.
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4-Benzoyl-5-[2-(4-Chlorophenyl)-Vinyl]-Isoxazole-
3-Carboxylic Acid Ethyl Ester, 2b
Yield = 75%; mp = 75–77°C (Et2O); 1H-NMR
(DMSO-d6) d 0.96 (t, 3H, CH3CH2, J = 7.2 Hz), 4.07
(q, 2H, CH3CH2, J = 7.2 Hz), 7.15 (d, 1H, CH = CH,
J = 16.8 Hz), 7.48 (m, 2H, Ar), 7.58 (m, 2H, Ar), 7.70–
7.78 (m, 4H: 3H, Ar; 1H, CH = CH), 7.82 (m, 2H, Ar).
MS m/z 382 [M+]. Anal. Calcd for C21H16ClNO4: C,
66.06; H, 4.22; N, 3.67. Found C, 66.22; H, 4.23; N, 3.68.
4-Benzoyl-5-[2-(3-Chlorophenyl)-Vinyl]-Isoxazole-
3-Carboxylic Acid Ethyl Ester, 2c
Yield = 67%; mp = 68–70°C (Et2O); 1H-NMR
(CDCl3) d 1.08 (t, 3H, CH3CH2, J = 7.2 Hz), 4.13 (q,
2H, CH3CH2, J = 7.2 Hz), 7.05 (d, 1H, CH = CH, J =
16.4 Hz), 7.30–7.40 (m, 3H, Ar), 7.50–7.60 (m, 4H: 3H,
Ar; 1H, CH = CH), 7.65 (m, 1H, Ar), 7.82 (m, 2H,
Ar). MS m/z 382 [M+]. Anal. Calcd for C21H16ClNO4:
C, 66.06; H, 4.22; N, 3.67. Found C, 66.20; H, 4.21;
N, 3.67.
4-Benzoyl-5-(2-Naphthalen-1-yl-Vinyl)-Isoxazole-3-
Carboxylic Acid Ethyl Ester, 2d
Yield = 48%; mp = 137–139°C (Et2O); 1H-NMR
(DMSO-d6) d 1.00 (t, 3H, CH3CH2, J = 7.2 Hz), 4.10
(q, 2H, CH3CH2, J = 7.2 Hz), 7.24 (d, 1H, CH = CH,
J = 16.4), 7.50–7.65 (m, 5H, Ar), 7.73 (m, 1H, Ar), 7.90
(m, 2H, Ar), 7.95 (m, 1H, Ar), 7.98–8.04 (m, 2H, Ar),
8.20 (m, 1H, Ar), 8.40 (d, 1H, CH = CH, J = 16.4 H).
MS m/z 398 [M+]. Anal. Calcd for C25H19NO4: C, 75.55;
H, 4.82; N, 3.52. Found C, 75.31; H, 4.81; N, 3.51.
4-(4-Chlorobenzoyl)-5-(2-Naphthalen-1-yl-Vinyl)-
Isoxazole-3-Carboxylic Acid Ethyl Ester, 2e
Yield = 28%; mp = 125–126°C (EtOH); 1H-NMR
(CDCl3) d 1.20 (t, 3H, CH3CH2, J = 7.2 Hz), 4.24 (q,
2H, CH3CH2, J = 7.2 Hz), 7.12 (d, 1H, CH = CH,
J = 16.4 Hz), 7.50 (d, 2H, Ar, J = 8.4 Hz), 7.57–7.64 (m,
3H, Ar), 7.77 (m, 1H, Ar), 7.80–7.90 (m, 2H, Ar), 7.92
(d, 2H, Ar, J = 8.4 Hz), 8.17 (m, 1H, Ar), 8.48 (d, 1H,
CH = CH, J = 16.4 Hz). MS m/z 432 [M+]. Anal. Calcd
for C25H18ClNO4: C, 69.53; H, 4.20; N, 3.24. Found C,
69.69; H, 4.21; N, 3.23.
4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-
Carboxylic Acid Ethyl Ester, 2f
Yield = 47%; mp = 128–129°C (EtOH); 1H-NMR
(CDCl3) d 1.10 (t, 3H, CH3CH2, J = 7.2 Hz), 4.15 (q,
2H, CH3CH2, J = 7.2 Hz), 7.10 (d, 1H, CH = CH,
J = 16.4 Hz), 7.40 (m, 1H, Ar), 7.46–7.55 (m, 5H, Ar),
7.60–7.65 (m, 6H, Ar), 7.70 (d, 1H, CH = CH, J =
16.4 Hz), 7.85 (m, 2H, Ar). MS m/z 424 [M+]. Anal.
Calcd for C27H21NO4: C, 76.58; H, 5.00; N, 3.31. Found
C, 76.77; H, 4.99; N, 3.32.
4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-
Carboxylic Acid, 3b
To a suspension of 2f (0.28 mmol) in 2.5 ml of
EtOH, 1 ml of 1N NaOH was added, and the mixture
was stirred at room temperature for 1 h. After cooling,
the mixture was acidified with 2N HCl and extracted
with ethyl acetate (3 x 10 ml). Evaporation of the
solvent under vacuum afforded the desired final com-
pound. Yield = 73%; mp = 187–190°C (EtOH); 1H-
NMR (CDCl3) d 6.70 (d, 1H, CH = CH, J = 16.4 Hz),
7.36–7.68 (m, 11H: 10H, Ar; 1H, CH = CH), 7.70–7.87
(m, 3H, Ar), 8.05 (m, 2H, Ar). MS m/z 396 [M+]. Anal.
Calcd for C25H17NO4: C, 75.94; H, 4.33; N, 3.54. Found
C, 75.73; H, 4.34; N, 3.54.
General Procedure for Compounds 4a–c
To a mixture of 3a [Renzi et al., 1968] and 3b
(0.313 mmol) in 1.5–2 ml of the appropriate alcohol
(methanol or isopropyl alcohol), 0.5 ml of conc. H2SO4
was added. The suspension was refluxed for 30–
120 min, and after cooling, cold water was added, and
the mixture was extracted with CH2Cl2 (3 ¥ 15 ml). The
solvent was evaporated in vacuum affording final com-
pounds 4a and 4b. For compound 4c, after dilution
with water, the precipitate was recovered by suction
and recrystallized with ethanol.
4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid
Methyl Ester, 4a
Yield = 94%; oil; 1H-NMR (CDCl3) d 3.70 (s, 3H,
CH3), 7.03 (d, 1H, CH = CH, J = 16.4 Hz), 7.36–7.40
(m, 3H, Ar), 7.45–7.55 (m, 4H, Ar), 7.60–7.70 (m, 2H:
1H, Ar; 1H, CH = CH), 7.82 (d, 2H, Ar). MS m/z 334
[M+]. Anal. Calcd for C20H15NO4: C, 72.06; H, 4.54; N,
4.20. Found C, 72.27; H, 4.55; N, 4.21.
4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid
Isopropyl Ester, 4b
Yield = 92%; oil; 1H-NMR (CDCl3) d 1.06 (d, 6H,
CH(CH3)2, J = 6.4 Hz), 5.03 (m, 1H, CH(CH3)2), 7.05
(d, 1H, CH = CH, J = 16.4 Hz), 7.35–7.40 (m, 3H, Ar),
7.42–7.55 (m, 4H, Ar), 7.60–7.70 (m, 2H: 1H, Ar; 1H,
CH = CH), 7.85 (d, 2H, Ar). MS m/z 362 [M+]. Anal.
Calcd for C20H15NO4: C, 73.12; H, 5.30; N, 3.88. Found
C, 72.91; H, 5.29; N, 3.89.
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4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-
Carboxylic Acid Isopropyl Ester, 4c
Yield = 65%; mp = 123–125°C (EtOH); 1H-NMR
(CDCl3) d 1.07 (d, 6H, CH(CH3)2, J = 6.4 Hz), 5.03
(m, 1H, CH(CH3)2), 7.10 (d, 1H, CH = CH,
J = 16.4 Hz), 7.35–7.56 (m, 6H, Ar), 7.60–7.77 (m,
6H: 5H, Ar, 1H, CH = CH), 7.82 (m, 1H, Ar), 7.85 (d,
2H, Ar). MS m/z 438 [M+]. Anal. Calcd for C28H23NO4:
C, 76.87; H, 5.30; N, 3.20. Found C, 76.85; H, 5.29; N,
3.21.
General Procedure for Compounds 7d and 7e
To a stirred mixture of the commercially available
5d or 5e (5,26 mmol) and diethyl oxalate (5–15 mmol)
in anhydrous ether (50 ml), 5.25–7.40 mmol of Na
was added in a dropwise manner. The suspension was
stirred at room temperature for 4 h and then heated at
40°C for 4–7 h. After cooling, the precipitate was fil-
tered off and washed with anhydrous ether. The solid
was dissolved in water and acidified with 6N HCl to
afford a crude precipitate that was collected by suction
and purified by crystallization from ethanol.
4-Hydroxy-4-(7-Methoxybenzofuran-2-yl)-2-oxo-
but-3-Enoic Acid Ethyl Ester, 7d
Yield = 85%; mp = 108–111°C (EtOH); 1H-NMR
(CDCl3) d 1.45 (t, 3H, CH3CH2, J = 7.2 Hz), 4.07 (s,
3H, OCH3), 4.42 (q, 2H, CH3CH2, J = 7.2 Hz), 7.00 (m,
1H, Ar), 7.20 (s, 1H, Ar), 7.25–7.33 (m, 2H, Ar), 7.65
(s, 1H, Ar). MS m/z 291 [M+]. Anal. Calcd for C15H14O6:
C, 62.07; H, 4.86. Found C, 62.22; H, 4.85.
4-(2,6-Dimethoxypyridin-3-yl)-4-Hydroxy-2-oxo-
but-3-Enoic Acid Ethyl Ester, 7e
Yield = 84%; mp = 86–89°C (EtOH); 1H-NMR
(CDCl3) d 1.43 (t, 3H, CH3CH2, J = 7.2 Hz), 4.03 (s,
3H, OCH3), 4.12 (s, 3H, OCH3), 4.40 (q, 2H, CH3CH2,
J = 7.2 Hz), 6.45 (d, 1H, Ar, J = 8.8 Hz), 7.41 (s, 1H,
Ar), 8.28 (d, 1H, Ar, J = 8.8 Hz). MS m/z 282 [M+].
Anal. Calcd for C13H15NO6: C, 55.51; H, 5.38; N, 4.98.
Found C, 55.68; H, 5.37; N, 4.99
General Procedure for Compounds 8b, 8d-g
To a suspension of 7b [Thormann et al., 2008] or
7d-g [Janculev and Podolesov, 1961; Patil et al., 2007;
Deavegowda et al., 2010] (0.51 mmol) and hydroxy-
lamine hydrochloride (2.5–3.02 mmol, dissolved in
0.5 ml of water) in 2–6 ml of EtOH, 0.3–0.4 ml of conc.
H2SO4 was added. The mixture was heated at 80°C for
15–45 min. After cooling, the solvent was evaporated
under vacuum to afford a residue which, after treat-
ment with cold water (15 ml), gave rise to a crude
precipitate that was recovered by suction. The final
compounds 8b, 8e, and 8g were purified by crystalli-
zation, whereas compounds 8d and 8f were purified by
column chromatography using toluene/ethyl acetate
9.5:0.5 as eluent.
5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic
Acid Ethyl Ester, 8b
Yield = 69%; mp = 130–131°C, dec. (EtOH);
1H-NMR (CDCl3) d 1.47 (t, 3H, CH3CH2, J = 7.2 Hz),
4.51 (q, 2H, CH3CH2, J = 7.2 Hz), 6.92 (s, 1H, isox-
azole), 7.45 (m, 2H, Ar), 7.85 (s, 1H, Ar), 7.90 (m, 2H,
Ar). MS m/z 274 [M+]. Anal. Calcd for C14H11NO3S: C,
61.52; H, 4.06; N, 5.12. Found C, 61.64; H, 4.07; N,
5.11.
5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-
Carboxylic Acid Ethyl Ester, 8d
Yield = 40%; mp = 119–121°C; purified by
column chromatography (toluene/ethyl acetate 9.5:0.5);
1H-NMR (CDCl3) d 1.45 (t, 3H, CH3CH2, J = 7.2 Hz),
4.07 (s, 3H,OCH3), 4.50 (q, 2H, CH3CH2, J = 7.2 Hz),
6.93 (m, 1H, Ar), 7.14 (s, 1H, isoxazole), 7.24–7.30 (m,
2H, Ar), 7.36 (s, 1H, Ar). MS m/z 288 [M+]. Anal. Calcd
for C15H13NO5: C, 62.72; H, 4.56; N, 4.88. Found C,
62.94; H, 4.57; N, 4.87.
5-(2,6-Dimethoxypyridin-3-yl)-Isoxazole-3-
Carboxylic Acid Ethyl Ester, 8e
Yield = 82%; mp = 131–133°C, (Ether); 1H-NMR
(CDCl3) d 1.47 (t, 3H, CH3CH2, J = 7.2 Hz), 4.01 (s,
3H, OCH3), 4.13 (s, 3H, OCH3), 4.50 (q, 2H, CH3CH2,
J = 7.2 Hz), 6.48 (d, 1H, Ar, J = 8.4 Hz), 7.05 (s, 1H,
isoxazole), 8.19 (d, 1H, Ar, J = 8.4 Hz). MS m/z 279
[M+]. Anal. Calcd for C13H14N2O5: C, 56,11; H, 5,07; N,
10,07. Found C, 56.24; H, 5.06; N, 10.04.
5-(9H-Fluoren-2-yl)-Isoxazole-3-Carboxylic Acid
Ethyl Ester, 8f
Yield = 68%; mp = 158–161°C, dec.; purified by
column chromatography (toluene/ethyl acetate 9.5:0.5);
1H-NMR (CDCl3) d 1.46 (t, 3H, CH3CH2, J = 7.2 Hz),
4.02 (s, 2H, PhCH2Ph), 4.51 (q, 2H, CH3CH2,
J = 7.2 Hz), 6.98 (s, 1H, isoxazole), 7.38–7.47 (m, 2H,
Ar), 7.61 (m, 1H, Ar), 7.85–7.92 (m, 3H, Ar), 8.03 (s,
1H, Ar). MS m/z 306 [M+]. Anal. Calcd for C19H15NO3:
C, 74.74; H, 4.95; N, 4.59. Found C, 74.56; H, 4.96;
N, 4.58.
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5-Anthracen-9-yl-Isoxazole-3-Carboxylic Acid Ethyl
Ester, 8g
Yield = 74%; mp = 139–141°C, (EtOH); 1H-NMR
(CDCl3) d 1.53 (t, 3H, CH3CH2, J = 7.2 Hz), 4.60 (q, 2H,
CH3CH2, J = 7.2 Hz), 7.09 (s, 1H, isoxazole), 7.51–7.57
(m, 4H, Ar), 7.80 (m, 2H, Ar), 8.10 (m, 2H, Ar), 8.67 (s,
1H, Ar). MS m/z 318 [M+]. Anal. Calcd for C20H15NO3:
C, 75.70; H, 4.76; N, 4.41. Found C, 75.88; H, 4.76;
N, 4.42.
General Procedure for 9b and 9d,e
A mixture of 8b or 8d,e (0.91 mmol) and 1N
NaOH (1–1.5 ml) in 3–4 ml of EtOH was stirred at
room temperature for 20–30 min. For compound 9b,
the suspension was heated at 50°C for 30 min. After
evaporation of the solvent under vacuum, water was
added, and the suspension was acidified with 6N HCl
(1–2 ml). The crude precipitate was recovered by
suction (compounds 9b and 9d), whereas compound
9e was extracted with ethyl acetate (3 ¥ 20 ml).
5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic
Acid, 9b
Yield = 47%; mp = 192–195°C, dec.; (EtOH); 1H-
NMR (DMSO-d6) d 7.41 (s, 1H, isoxazole), 7.49 (m, 2H,
Ar), 7.99 (m, 1H, Ar), 8.10 (m, 1H, Ar), 8.18 (s, 1H, Ar).
MS m/z 246 [M+]. Anal. Calcd for C12H7NO3S: C, 58.77;
H, 2.88; N, 5.71. Found C, 58.94; H, 2.87; N, 5.73.
5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-
Carboxylic Acid, 9d
Yield = 76%; mp = 179–182°C, dec.; (EtOH);
1H-NMR (DMSO-d6) d 3.99 (s, 3H, OCH3), 7.09 (m,
1H, Ar), 7.27–7.35 (m, 3H: 2H, Ar; 1H, isoxazole),
7.72 (s, 1H, Ar). MS m/z 260 [M+]. Anal. Calcd for
C13H9NO5: C, 60.24; H, 3.50; N, 5.40 Found C, 60.36;
H, 3.51; N, 5.41.
5-(2,6-Dimethoxypyridin-3-yl)-Isoxazole-3-
Carboxylic Acid, 9e
Yield = 56%; mp = 200–203°C, dec.; (EtOH);
1H-NMR (DMSO-d6) d 3.96 (s, 3H, OCH3), 4.08 (s, 3H,
OCH3), 6.59 (d, 2H, Ar, J = 8.4 Hz), 6.97 (s, 1H, isox-
azole), 8.21 (d, 2H, Ar, J = 8.4 Hz). MS m/z 251 [M+].
Anal. Calcd for C11H10N2O5: C, 52.80; H, 4.03; N, 11.20.
Found C, 52.94; H, 4.02; N, 11.17.
General Procedure for 10a–e
Compounds 10a–e were obtained starting from
9a–e (compounds 9a [Fatutta and Balestra, 1958] and
9c [Schneider et al., 2008]) following the general
procedure described for compounds 4a–c. For com-
pounds 10b–d, after dilution with cold water, the
precipitate was recovered by suction and purified by
crystallization, whereas compound 10e was purified
by column chromatography using cyclohexane/ethyl
acetate 1/1 as eluent.
5-Biphenyl-4-yl-Isoxazole-3-Carboxylic Acid
Isopropyl Ester, 10a
Yield = 55%; mp = 101–103°C; (EtOH); 1H-NMR
(CDCl3) d 1.46 (d, 6H, CH(CH3)2, J = 6.4 Hz), 5.32–
5.42 (m, 1H, CH(CH3)2), 6.97 (s, 1H, isoxazole), 7.43 (m,
1H, Ar), 7.50 (m, 2H, Ar), 7.67 (m, 2H, Ar), 7.75 (d, 2H,
Ar, J = 8.4 Hz), 7.92 (d, 2H, Ar, J = 8.4 Hz). MS m/z 308
[M+]. Anal. Calcd for C19H17NO3: C, 74.25; H, 5.58; N,
4.56. Found C, 74.50; H, 5.56; N, 4.57.
5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic
Acid Isopropyl Ester, 10b
Yield = 85%; mp = 101–103°C, (cicloexane); 1H-
NMR (CDCl3) d 1.46 (d, 6H, CH(CH3)2, J = 6.4 Hz),
5.32–5.41 (m, 1H, CH(CH3)2), 6.91 (s, 1H, isoxazole),
7.45 (m, 2H, Ar), 7.85 (s, 1H, Ar), 7.89 (m, 2H, Ar). MS
m/z 288 [M+]. Anal. Calcd for C15H13NO3S: C, 62.70; H,
4.56; N, 4.87. Found C, 62.87; H, 4.57; N, 4.86.
5-Thiophen-2-yl-Isoxazole-3-Carboxylic Acid
Isopropyl Ester, 10c
Yield = 59%; mp = 53–56°C, (EtOH); 1H-NMR
(CDCl3) d 1.44 (d, 6H, CH(CH3)2, J = 6.4 Hz), 5.35 (m,
1H, CH(CH3)2), 6.79 (s, 1H, isoxazole), 7.17 (m, 1H,
Ar), 7.52 (m, 1H, Ar), 7.59 (m, 1H, Ar). MS m/z 238
[M+]. Anal. Calcd for C11H11NO3S: C, 55.68; H, 4.67; N,
5.90. Found C, 55.89; H, 4.67; N, 5.88.
5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-
Carboxylic Acid Isopropyl Ester, 10d
Yield = 82%; mp = 96–100°C; purified by column
chromatography (cicloexane/ethyl acetate 1:1); 1H-
NMR (CDCl3) d 1.45 (d, 6H, CH(CH3)2, J = 6.4 Hz),
4.07 (s, 3H, OCH3), 5.35 (m, 1H, CH(CH3)2), 6.93
(m, 1H, Ar), 7.13 (s, 1H, isoxazole), 7.26 (m, 2H, Ar),
7.36 (s, 1H, Ar). MS m/z 302 [M+]. Anal. Calcd for
C16H15NO5: C, 63.78; H, 5.02; N, 4.65. Found C, 63.59;
H, 5.04; N, 4.66.
5-(2,6-Dimethoxypyridin-3-yl)-Isoxazole-3-
Carboxylic Acid Isopropyl Ester, 10e
Yield = 86%; mp = 119–121°C, (EtOH); 1H-NMR
(CDCl3) d 1.45 (d, 6H, CH(CH3)2, J = 6.4 Hz), 4.00
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(s, 3H, OCH3), 4.13 (s, 3H, OCH3), 5.35 (m, 1H,
CH(CH3)2), 6.48 (d, 1H, Ar, J = 8.4 Hz), 7.04 (s, 1H,
isoxazole), 8.19 (d, 1H, Ar, J = 8.4 Hz). MSm/z 293 [M+].
Anal. Calcd for C14H16N2O5: C, 57.53; H, 5.52; N, 9.58.
Found C, 57.82; H, 5.53; N, 9.61.
Biological Assays
Microplate Almar blue assay (MABA)
[Franzblau et al., 1998]
Test compound MICs against Mtb H37RV
(ATCC27294) were assessed by the MABA using RMP
and INH as positive controls. Compound stock solu-
tions were prepared in DMSO at concentration of
12.8 mM, and the final test concentrations ranged from
128 mM to 0.5 mM. Twofold dilutions of compounds
were prepared in Middlebrook 7H12 medium (7H9
broth containing 0.1% w/v casitone, 5.6 mg/ml palmitic
acid, 5 mg/ml bovine serum albumin, 4 mg/ml catalase,
filter-sterilizes) in a volume of 100 ml in 96-well micro-
plates (BD OptiluxTM, 96-well Microplates, black/clear
flat bottom; Becton,-Dickenson, Franklin Lakes, NJ
USA). Mtb cultures (100 ml inoculum of 2 ¥ 105 cfu/ml)
were added, yielding a final test volume of 200 ml. The
TABLE 1. Anti-TB Activity of Compounds 2a–f and 4a–c
N
O
ROOC
CH=CH-Ar
O
X
2a-f, 4a-c
Compound R Ar X MABAa MIC (mM) LORAa MIC (mM) Vero cell IC50 (mM)
2a C2H5 H 58.2 96.6 95.17
2b C2H5 Cl H 35.5 109.1 >128
2c C2H5
Cl
H 81.6 62.3 108.4
2d C2H5 H 26.9 54.7 >128
2e C2H5 Cl >128 >128 NDb
2f C2H5 H 114.6 101.3 111.5
4a CH3 H 26.8 54.1 88.07
4b iC3H7 H 61.2 >128 100.6
4c iC3H7 H 64.0 82.3 56.74
INH 0.4 >128 >128
RMP 0.1 1.9 110
PA-824 0.4 3.0 >128
aMtb strain H37Rv.
bNot determined.
INH, isoniazide; LORA, low oxygen recovery assay; MABA, microplate Alamar blue assay; MIC, minimum inhibitory concentration;
RMP, rifampin.
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plates were incubated at 37°C. On the seventh day of
incubation, 12.5 ml of 20% Tween 80 and 20 ml of
Alamar Blue (Invitrogen BioSourceTM; Life Technolo-
gies, Grand Island, NY USA) were added to the wells.
After incubation at 37°C for 16–24 h, well fluorescence
was measured (ex 530, em 590 nm). MICs were defined
as the lowest concentration effecting a reduction in
fluorescence of 90% relative to the mean of replicate
bacteria-only controls.
Low-Oxygen-Recovery Assay (LORA)
[Cho et al., 2007]
A low-oxygen adapted culture of recombinant
H37Rv (pFCA-luxAB), expressing a Vibrio harveyii
TABLE 2. Anti-TB Activity of Compounds 8a–g and 10a–e
N
O
ROOC
Ar
8a-g, 10a-e
Compound R Ar MABAa MIC (mM) LORAa MIC (mM) Vero cell IC50 (mM)
8a C2H5 3.3 30.1 102
8b C2H5
S
2.7 25.3 >128
8c C2H5
S
3.5 58.9 >128
8d C2H5
O
O
2.2 13.1 >128
8e C2H5
N
O
O
>128 >128 NDb
8f C2H5 >128 >128 NDb
8g C2H5 >128 >128 NDb
10a iC3H7 2.3 63.5 >128
10b iC3H7
S
11.4 26.6 >128
10c iC3H7
S
2.4 14.0 >128
10d iC3H7 O
O
5.6 7.3 >128
10e iC3H7 N
O
O
>128 >128 NDb
INH 0.4 >128 >128
RMP 0.1 1.9 >128
PA-824 0.4 3.0 >128
aMtb strain H37Rv.
bNot determined.
INH, isoniazide; LORA, low oxygen recovery assay; MABA, microplate Alamar blue assay; MIC, minimum inhibitory concentration;
RMP, rifampin.
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luciferase gene with an acetamidase promoter, was
grown in a BiostatQ fermentor (Sartorius Group, Got-
tingen, Germany). Cells were collected on ice, washed
in PBS, and stored at -80°C. Approximately 105 cfu/ml
of thawed NRP cells were exposed to twofold serial
dilutions of test compound in 7H9 broth in 96-well
plates, incubated for 10 days anaerobically at 37°C.
Luminescence readings were obtained following a 28-h
recovery in an aerobic environment (5% CO2). The data
were analyzed graphically, and the lowest concentration
of test compound preventing metabolic recovery (90%
reduction relative to untreated cultures) was deter-
mined as described previously.
Cytotoxicity Assay [Falzari et al., 2005]
Cytotoxicity was determined by exposing different
concentrations of samples to Vero cells. Briefly, samples
were dissolved at 12.8 mM in DMSO. Six threefold
dilutions were performed in growth medium MEM
(Gibco, Grand Island, NY, USA), containing 10% fetal
bovine serum (HyClone, Logan, UT, USA), 25 mM N-
(2-hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid
(HEPES, Gibco), 0.2% NaHCO3 (Gibco), and 2 mM
glutamine (Irvine Scientific, Santa Ana, CA, USA).
Final DMSO concentrations did not exceed 1% v/v.
Compound dilutions were assayed in duplicate in 96-
well tissue culture plates (Becton Dickinson Labware,
Lincoln Park, NJ, USA) in a volume of 50 ml per well.
An equal volume containing 5 ¥ 105 log phase Vero cells
(CCL-81; ATTC, Rockville, MD, USA) was added to
each well, and cultures were incubated at 37°C in 5%
CO2 atmosphere. After 72 h, cell viability was measured
using the CellTiter 96 aqueous nonradioactive cell pro-
liferation assay (Promega Corp. Madison, WI, USA)
according to the manufacturer’s instructions. Absor-
bance at 490 nm was read in a Victor2 multilabel reader
(Perkin Elmer). The IC50 values were determined using
a curve-fitting program.
RESULTS AND DISCUSSION
The activity of compounds 2a–f, 4a–c, 8a–g, and
10a–e was evaluated against Mtb TB strain H37Rv in a
MABA [Franzblau et al., 1998] and against NRP-TB in
a LORA [Cho et al., 2007] with the activity expressed as
MIC values (minimum inhibitory concentrations). Fur-
thermore, toxicity to Mtb an in vitro cytotoxicity test was
assessed using Vero cells. (Tables 1 and 2). INH, RMP,
and PA-824 were used as reference compounds.
Starting from 5-vinylisoxazoles 2a–f and 4a–c
(Table 1), compounds show a low activity against Mtb
with the only noteworthy observation being the differ-
ence of activity between compounds 2d and 2e, which
differ only by a chlorine in the para–position of benzoyl
fragment. Compound 2d was one of the more active in
this series (MIC = 26.9 mM) with 2e being inactive
(MIC > 128 mM), suggesting that the chlorine is detri-
mental to activity. For most compounds, there is a cor-
respondence between MABA and LORA values and
with the exception of compounds 2b and 2d (Vero cell
IC50 > 128 mM), they also showed little in vitro cytotox-
icity (Vero cell 56.74 < IC50 < 128 mM)
Data on the series of 5-(hetero)aryl-4-
unsubstituted isoxazoles 8a–g and 10a–e are shown in
Table 2. With the exception of compounds 8e, 8f, 8g,
and 10e improved activity was observed as compared
with the previous compounds. The residue R of the
ester function can be changed as the 3-ethyl and the
3-isopropyl ester derivatives show comparable activity.
However, there is a crucial role for the substituent
at position 5. Compounds with a diphenyl, thiophene,
benzothiophene, or a methoxybenzofurane had MIC
values in the low micromolar range (MIC = 2.2–
5.6 mM), whereas the introduction of aromatic portions
endowed with major bulk (fluorene and anthracene
nucleus) resulted to inactive compounds (8f and 8g,
MIC > 128 mM). The same inactivity was observed for
the two 5-(2,6-dimethoxypiridine) derivatives, 8e and
10e, that contain a strongly basic nitrogen. An analo-
gous activity trend occurred in the LORA, whereas
MIC values were approximately an order of magnitude
higher than in MABA. Moreover, with the exception of
8a, all active compounds had no toxicity in Vero cell
with IC50 values > 128 mM. These initial results suggest
that position 4 of the isoxazole ring must be unsubsti-
tuted and the ethylenic spacer must be deleted from
position 5 and the aromatic portion, with an appropriate
steric hindrance directly linked to C-5 isoxazole.
Further studies are in progress to better define the
requirements in the isoxazole scaffold to improve anti-
tubercular activity.
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